

Table 1.24
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

| All Races | | | White | | | Black | | |
|----------------------------|-------------------|------------------|----------------------------|-------------------|------------------|----------------------------|-------------------|------------------|
| | Rate ^b | APC ^c | | Rate ^b | APC ^c | | Rate ^b | APC ^c |
| | 2004-2008 | 1999-2008 | | 2004-2008 | 1999-2008 | | 2004-2008 | 1999-2008 |
| All Sites | 541.0 | -1.0* | All Sites | 543.6 | -1.0* | All Sites | 626.1 | -1.8* |
| Prostate | 156.0 | -2.0* | Prostate | 149.5 | -2.2* | Prostate | 233.8 | -2.7* |
| Lung and Bronchus | 75.2 | -2.1* | Lung and Bronchus | 75.3 | -2.1* | Lung and Bronchus | 99.8 | -2.8* |
| Colon and Rectum | 55.0 | -2.7* | Colon and Rectum | 54.4 | -2.9* | Colon and Rectum | 67.7 | -1.8* |
| Urinary Bladder | 37.5 | -0.4 | Urinary Bladder | 40.6 | -0.4 | Kidney and Renal Pelvis | 23.3 | 3.0* |
| Melanoma of the Skin | 26.7 | 2.0* | Melanoma of the Skin | 30.9 | 2.3* | Urinary Bladder | 21.6 | 0.4 |
| Non-Hodgkin Lymphoma | 24.0 | 0.1 | Non-Hodgkin Lymphoma | 25.0 | 0.2 | Non-Hodgkin Lymphoma | 17.9 | 0.0 |
| Kidney and Renal Pelvis | 20.0 | 2.8* | Kidney and Renal Pelvis | 20.5 | 2.5* | Stomach | 17.2 | -0.7 |
| Leukemia | 16.1 | -0.8* | Leukemia | 16.8 | -0.8 | Pancreas | 17.1 | 0.5 |
| Oral Cavity and Pharynx | 15.7 | -0.4 | Oral Cavity and Pharynx | 16.1 | -0.1 | Oral Cavity and Pharynx | 15.6 | -3.3* |
| Pancreas | 13.6 | 1.1* | Pancreas | 13.5 | 1.1* | Liver & IBD ^f | 15.1 | 3.8* |
| Liver & IBD ^f | 11.2 | 3.2* | Liver & IBD ^f | 9.6 | 3.7* | Myeloma | 14.5 | 0.5 |
| Stomach | 10.8 | -1.8* | Stomach | 9.5 | -1.9* | Leukemia | 12.9 | -0.5 |
| Esophagus | 7.8 | -0.8 | Brain and ONS ^f | 8.4 | -0.6 | Larynx | 9.8 | -3.9* |
| Brain and ONS ^f | 7.7 | -0.6* | Esophagus | 8.1 | -0.4 | Esophagus | 8.6 | -4.1* |
| Myeloma | 7.2 | -0.2 | Myeloma | 6.8 | -0.2 | Brain and ONS ^f | 4.6 | -1.3 |

| Asian/Pacific Islander | | | American Indian/Alaska Native ^d | | | Hispanic ^e | | |
|----------------------------|-------------------|------------------|--|-------------------|------------------|----------------------------|-------------------|------------------|
| | Rate ^b | APC ^c | | Rate ^b | APC ^c | | Rate ^b | APC ^c |
| | 2004-2008 | 1999-2008 | | 2004-2008 | 1999-2008 | | 2004-2008 | 1999-2008 |
| All Sites | 347.7 | -1.1* | All Sites | 338.0 | -1.3 | All Sites | 407.3 | -1.5* |
| Prostate | 88.3 | -2.0* | Prostate | 75.3 | -1.7 | Prostate | 129.0 | -2.8* |
| Lung and Bronchus | 53.2 | -1.3* | Lung and Bronchus | 51.2 | 0.0 | Colon and Rectum | 46.0 | -1.5* |
| Colon and Rectum | 45.4 | -2.2* | Colon and Rectum | 42.7 | -3.7 | Lung and Bronchus | 41.5 | -2.2* |
| Liver & IBD ^f | 22.1 | 0.6 | Kidney and Renal Pelvis | 22.1 | 3.1 | Urinary Bladder | 20.0 | -1.8* |
| Stomach | 17.2 | -3.1* | Liver & IBD ^f | 17.4 | 2.5 | Non-Hodgkin Lymphoma | 19.5 | 0.2 |
| Non-Hodgkin Lymphoma | 16.3 | -0.4 | Stomach | 14.7 | -3.9 | Kidney and Renal Pelvis | 19.2 | 2.8* |
| Urinary Bladder | 16.3 | 0.4 | Urinary Bladder | 14.0 | - | Liver & IBD ^f | 16.5 | 2.2* |
| Oral Cavity and Pharynx | 10.9 | 0.1 | Non-Hodgkin Lymphoma | 13.0 | - | Stomach | 14.9 | -1.9 |
| Kidney and Renal Pelvis | 10.6 | 5.0* | Pancreas | 11.4 | - | Leukemia | 11.7 | -0.5 |
| Pancreas | 10.6 | 2.1* | Leukemia | 9.1 | - | Pancreas | 11.4 | 1.3 |
| Leukemia | 8.9 | -1.8* | Oral Cavity and Pharynx | 9.1 | - | Oral Cavity and Pharynx | 9.0 | -0.9 |
| Thyroid | 4.9 | 3.1* | Esophagus | 5.9 | - | Myeloma | 6.4 | -1.2 |
| Esophagus | 4.2 | -1.4 | Myeloma | 4.9 | - | Brain and ONS ^f | 6.0 | -1.2 |
| Myeloma | 4.1 | -0.3 | Melanoma of the Skin | 3.9 | - | Esophagus | 5.2 | -4.5* |
| Brain and ONS ^f | 4.0 | -0.2 | Brain and ONS ^f | 3.8 | - | Melanoma of the Skin | 4.8 | 0.6 |

- ^a Top 15 cancer sites selected based on 2004-2008 age-adjusted rates for the race/ethnic group.
- ^b Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
- ^c Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- ^d Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
- ^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
- ^f Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- ^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- * The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.